Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 66 Head & Neck 23 CNS 20 Endocrine 15 Tumor-Agnostic 13 Gastrointestinal 9 Thoracic 8 Plasma cell 7 Other hematologic neoplasm 7 Lymphoid 5 Myeloid 4 Sarcoma 2 Other solid neoplasm 2 Gynecologic 2 Genitourinary 2 Breast 2 Other neoplasm 1 Classical hematology 1

Conditions

Rare Malignant Neoplasm 1

Interventions

Cyclophosphamide 13 Peripheral Blood Stem Cell Transplantation 9 Biopsy 9 fludarabine phosphate 8 Busulfan 8 Whole-Body Irradiation 7 Surveys and Questionnaires 6 Mycophenolic Acid 6 Educational Status 6 Early Intervention, Educational 6 Carboplatin 6 fludarabine 5 Tacrolimus 5 Paclitaxel 5 Methotrexate 5 Methods 5 Melphalan 5 Epoetin Alfa 5 Decitabine 5 Cyclosporine 5 Colposcopy 5 Cisplatin 5 Celecoxib 5 Antilymphocyte Serum 5 Aminolevulinic Acid 5 Sulindac 4 Selenium 4 Radiotherapy 4 Patient Reported Outcome Measures 4 Magnetic Resonance Spectroscopy 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × dabrafenib × Other neoplasm × Clear all

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡